rituximab
FDA accepts license application for Novartis’ rituximab biosimilar
September 12, 2017Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab
Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …
Investigational antibody boosts chemotherapy’s cancer-killing potential
June 29, 2017Research and Development CFH, Cancer, oncology, rituximab
A proof-of-concept study conducted at the Duke Cancer Institute (DCI) in North Carolina has shown that an investigational antibody has …
UK launch of two Novartis biosimilars could cut NHS costs
June 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab
Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
Novartis challenges Roche with MabThera biosimilar
January 11, 2011Research and Development Lonza MabThera, Novartis, Roche, Teva, biosimilar, rituximab
Novartis’ generics unit Sandoz has begun mid-stage trials of a biosimilar version of Roche’s blockbuster drug MabThera. The phase II …
NICE recommends MabThera for non-Hodgkin’s lymphoma
December 6, 2010Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab
NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …
ASCO cancer conference opens
June 4, 2010Research and Development ASCO, Cancer, lenalidomide, rituximab
One of the most important dates in the pharmaceutical industry’s calendar, the ASCO cancer conference begins today. The American Society …
